Trial Profile
A Special Access Program of NERLYNX (neratinib)
Status:
Planning
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer; Haematological malignancies; Solid tumours
- Focus Expanded access; Therapeutic Use
- 28 Nov 2017 New trial record
- 22 Nov 2017 According to a Specialised Therapeutics Asia media release, the company is planning to initiate this program in Q1 2018.